PT  - JOURNAL ARTICLE
AU  - QINGHONG HAN
AU  - ROBERT M. HOFFMAN
TI  - Chronic Treatment of an Advanced Prostate-cancer Patient With Oral Methioninase Resulted in Long-term Stabilization of Rapidly Rising PSA Levels
AID  - 10.21873/invivo.12488
DP  - 2021 Jul 01
TA  - In Vivo
PG  - 2171--2176
VI  - 35
IP  - 4
4099  - http://iv.iiarjournals.org/content/35/4/2171.short
4100  - http://iv.iiarjournals.org/content/35/4/2171.full
SO  - In Vivo2021 Jul 01; 35
AB  - Background/Aim: Advanced prostate cancer is a recalcitrant disease with very limited treatment options. Our laboratory discovered methionine addiction, presumably a characteristic of all cancer types, including prostate cancer, which can be targeted by methionine restriction (MR), through treatment with oral recombinant methioninase (o-rMETase). Patients and Methods: o-rMETase was produced by fermentation of recombinant E. coli containing the Pseudomonas putida methioninase gene, and purified by column chromatography. An advanced prostate cancer patient received o-rMETase as a supplement, 500 units per day, divided into two oral doses of 250 units each. Results: Before treatment, the patient had a rapid rise in PSA levels, from 39 to 56 ng/ml, within 6 weeks. At the 15th week of o-rMETase administration, the PSA levels stabilized at 62 ng/ml. No overt side effects were observed. Conclusion: o-rMETase single treatment can be beneficial for advanced prostate cancer patients.